MedPath

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Phase 2
Completed
Conditions
Sarcoma, Kaposi
HIV Infections
Registration Number
NCT00000807
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To assess the toxicity, tumor response rate, and effect on quality of life of daily low-dose etoposide administered for 7 consecutive days every other week in patients with AIDS-related Kaposi's sarcoma that has relapsed or progressed after systemic chemotherapy.

Etoposide may be at least as, or even more, effective and less myelotoxic when given in low doses over prolonged periods of time.

Detailed Description

Etoposide may be at least as, or even more, effective and less myelotoxic when given in low doses over prolonged periods of time.

Patients receive low-dose oral etoposide on days 1 through 7 of every 2-week cycle. Patients who achieve a complete or partial response after two cycles and have no toxicity greater than grade 2 may have their dose escalated for subsequent cycles. If there are no responses to therapy among the first 14 evaluable patients, the study will close; if there is at least one objective response to therapy among the first 14 evaluable patients, enrollment will continue until all 41 patients are enrolled. Patients continue therapy until maximal tumor response (either stable disease or complete response) is achieved or disease progression occurs.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (20)

Univ of Southern California / LA County USC Med Ctr

🇺🇸

Los Angeles, California, United States

Northwestern Univ Med School

🇺🇸

Chicago, Illinois, United States

Boston Med Ctr

🇺🇸

Boston, Massachusetts, United States

Univ of Colorado Health Sciences Ctr

🇺🇸

Denver, Colorado, United States

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

San Francisco Gen Hosp

🇺🇸

San Francisco, California, United States

Denver Dept of Health and Hosps

🇺🇸

Denver, Colorado, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Albany Med College / Division of HIV Medicine A158

🇺🇸

Albany, New York, United States

Mid - Hudson Care Ctr

🇺🇸

Albany, New York, United States

Yale Univ / New Haven

🇺🇸

New Haven, Connecticut, United States

Julio Arroyo

🇺🇸

West Columbia, South Carolina, United States

K Norris Cancer Hosp / Los Angeles County - USC Med Ctr

🇺🇸

Los Angeles, California, United States

Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Columbia Presbyterian Med Ctr

🇺🇸

New York, New York, United States

Mount Sinai Med Ctr

🇺🇸

New York, New York, United States

Adirondack Med Ctr at Saranac Lake

🇺🇸

Albany, New York, United States

Saint Clare's Hosp and Health Ctr

🇺🇸

New York, New York, United States

SUNY / Erie County Med Ctr at Buffalo

🇺🇸

Buffalo, New York, United States

City Hosp Ctr at Elmhurst / Mount Sinai Hosp

🇺🇸

Elmhurst, New York, United States

© Copyright 2025. All Rights Reserved by MedPath